Log in

Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) Given Average Rating of "Hold" by Analysts

Last updated on Monday, September 28, 2020 | 2020 MarketBeat

Shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) have earned an average rating of "Hold" from the nineteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $8.75.

Several research firms have weighed in on MDRX. Deutsche Bank cut their target price on shares of Allscripts Healthcare Solutions from $11.00 to $9.00 and set a "hold" rating on the stock in a report on Thursday, June 11th. Cantor Fitzgerald increased their price objective on shares of Allscripts Healthcare Solutions from $6.00 to $9.00 and gave the stock a "neutral" rating in a research report on Friday, July 31st. Canaccord Genuity reissued a "buy" rating on shares of Allscripts Healthcare Solutions in a research report on Friday, July 31st. TheStreet raised shares of Allscripts Healthcare Solutions from a "d" rating to a "c-" rating in a research report on Friday, July 31st. Finally, Morgan Stanley increased their price objective on shares of Allscripts Healthcare Solutions from $6.00 to $8.00 and gave the stock an "underweight" rating in a research report on Tuesday, August 11th.

A number of institutional investors have recently added to or reduced their stakes in MDRX. Fisher Asset Management LLC grew its position in Allscripts Healthcare Solutions by 20.8% in the second quarter. Fisher Asset Management LLC now owns 6,438,309 shares of the software maker's stock valued at $43,587,000 after purchasing an additional 1,108,618 shares in the last quarter. Principal Financial Group Inc. grew its position in Allscripts Healthcare Solutions by 176.8% in the second quarter. Principal Financial Group Inc. now owns 1,385,371 shares of the software maker's stock valued at $9,379,000 after purchasing an additional 884,870 shares in the last quarter. Vanguard Group Inc. grew its position in Allscripts Healthcare Solutions by 4.5% in the second quarter. Vanguard Group Inc. now owns 17,719,701 shares of the software maker's stock valued at $119,963,000 after purchasing an additional 758,892 shares in the last quarter. Nuveen Asset Management LLC grew its position in Allscripts Healthcare Solutions by 49.3% in the first quarter. Nuveen Asset Management LLC now owns 1,384,129 shares of the software maker's stock valued at $9,744,000 after purchasing an additional 457,101 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC grew its position in shares of Allscripts Healthcare Solutions by 3,698.1% in the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 398,800 shares of the software maker's stock valued at $2,700,000 after acquiring an additional 388,300 shares during the period.

MDRX traded up $0.15 during mid-day trading on Monday, hitting $8.21. The stock had a trading volume of 950,404 shares, compared to its average volume of 2,112,434. The stock's fifty day simple moving average is $8.84 and its 200-day simple moving average is $7.18. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.78 and a quick ratio of 0.78. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -24.88, a price-to-earnings-growth ratio of 2.02 and a beta of 1.08. Allscripts Healthcare Solutions has a 1-year low of $4.56 and a 1-year high of $11.82.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last posted its earnings results on Thursday, July 30th. The software maker reported $0.18 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.08 by $0.10. The company had revenue of $406.20 million for the quarter, compared to analyst estimates of $399.80 million. Allscripts Healthcare Solutions had a negative net margin of 3.06% and a positive return on equity of 5.55%. As a group, research analysts expect that Allscripts Healthcare Solutions will post 0.49 earnings per share for the current fiscal year.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.

Featured Article: Death Cross

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

13 Stocks Institutional Investors Won't Stop Buying

University endowments, pension funds, sovereign wealth funds, hedge funds and other institutional investors have recently been pouring money into a a group of 13 elite stocks.

These institutional investors don't get easily swayed by hot stocks that are popular with retail investors. You probably won't see a Tesla or a SnapChat in this group, because institutional investors know that these "popular kid" stocks almost always aren't great investments. However, you will find some incredibly solid companies on this list backed by real earnings and real fundamentals.

In order to identify these stocks, we had to comb through every 13D and 13F filing that institutional investors have filed with the SEC in the last quarter. After reviewing more than 5,000 filings, we have identified 13 companies that institutional investors have been buying left. Big money investors are pouring hundreds of millions of dollars into these stocks.

View the "13 Stocks Institutional Investors Won't Stop Buying".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.